U.S. Markets close in 5 hrs 56 mins
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    110.30
    +1.87 (+1.72%)
     
  • Gold

    1,807.40
    +5.90 (+0.33%)
     
  • Silver

    19.86
    +0.19 (+0.98%)
     
  • EUR/USD

    1.0428
    +0.0001 (+0.0104%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2109
    +0.0006 (+0.0484%)
     
  • USD/JPY

    135.6670
    +0.4920 (+0.3640%)
     
  • BTC-USD

    19,409.97
    -129.71 (-0.66%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Acadia Pharmaceuticals Inc. ACAD announced top-line data from a phase II study evaluating its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery.

The double-blind, placebo-controlled phase II study evaluated the safety and efficacy of ACP-044 for the given indication. The study failed to meet the primary endpoint, which was a comparison of cumulative pain intensity scores over 24 hours between the once daily ACP-044 (1600 mg), four times daily ACP-044 (400 mg) and placebo treatment arms.

Per the company, a favorable trend was observed on the primary endpoint in the ACP-044 (400 mg) once every six hours treatment group. Despite showing consistent improvement from placebo, these trends were not statistically significant at 48 hours and 72 hours.

Shares of Acadia were down 5.4% in after-hours trading on Monday following the announcement of the news. The stock has declined 4% so far this year compared with the industry’s decrease of 13.4%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In March 2021, the company initiated a phase II study on ACP-044 for treating postoperative pain following bunionectomy surgery.

Acadia is also evaluating ACP-044 in an ongoing study for treating pain associated with osteoarthritis. The study is expected to complete in the first half of 2023.

Acadia has other promising pipeline candidates that are progressing well.

In December 2021, the company announced positive top-line data from the phase III Lavender study, which evaluated the safety and efficacy of its candidate, trofinetide, for the treatment of Rett syndrome. The study met its co-primary endpoints.

Acadia expects to file a new drug application for trofinetide to treat Rett syndrome around mid-2022.

Acadia’s sole marketed drug, Nuplazid (pimavanserin), is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Acadia has resubmitted the supplemental new drug application (sNDA) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”) in February 2022. With this resubmission of the sNDA for pimavanserin, the company is now narrowing down the focus of the proposed indication from dementia-related psychosis to ADP. The FDA has set a target action date of Aug 4, 2022.

In 2021, Nuplazid recorded sales worth $484.1 million, reflecting an increase of 10% year over year. A potential label expansion is likely to boost sales of the drug in 2022 and beyond.

Zacks Rank & Stocks to Consider

Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Aligos Therapeutics, Inc. ALGS, Applied Therapeutics, Inc. APLT and Voyager Therapeutics, Inc. VYGR, all carrying the same Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Aligos Therapeutics’ loss per share has narrowed 15.1% for 2022 and 45.7% for 2023 over the past 60 days.

Earnings of ALGS surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

Applied Therapeutics’ loss per share estimates have narrowed 35.8% for 2022 and 32.7% for 2023 over the past 60 days.

Earnings of Applied Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion.

Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 232.4% year to date.

Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report

Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report

Applied Therapeutics Inc. (APLT) : Free Stock Analysis Report

Aligos Therapeutics, Inc. (ALGS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research